HYLENEX Recombinant (Halozyme, Inc.)


Welcome to the PulseAid listing for the HYLENEX Recombinant drug offered from Halozyme, Inc.. This Endoglycosidase [EPC],Glycoside Hydrolases [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Halozyme, Inc.
NON-PROPRIETARY NAME: Hyaluronidase (Human Recombinant)
SUBSTANCE NAME: HYALURONIDASE (HUMAN RECOMBINANT)
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Endoglycosidase [EPC],Glycoside Hydrolases [Chemical/Ingredient]
ROUTE: SUBCUTANEOUS
DOSAGE FORM: INJECTION, SOLUTION
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2005-12-02
END MARKETING DATE: 0000-00-00


HYLENEX Recombinant HUMAN PRESCRIPTION DRUG Details:

Item DescriptionHYLENEX Recombinant from Halozyme, Inc.
LABELER NAME: Halozyme, Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 150([USP’U]/mL)
START MARKETING DATE: 2005-12-02
END MARKETING DATE: 0000-00-00
PRODUCT ID: 18657-117_308df247-a446-4284-8a1a-04410cd25e52
PRODUCT NDC: 18657-117
APPLICATION NUMBER: NDA021859

Other HYALURONIDASE (HUMAN RECOMBINANT) Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Halozyme, Inc.HYLENEX Recombinant